Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanabenz add-on therapy in amyotrophic lateral sclerosis
2014-005367-32Phase 2Completed
- Sponsor
- Carlo Besta Neurological Institute
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of guanabenz in amyotrophic lateral sclerosis (ALS), sponsored by Carlo Besta Neurological Institute. Started Mar 2017; status: completed.
02
Drugs
guanabenz
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2014-005367-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005367-32.